Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis

The term heparin resistance (HR) is used by clinicians without specific criteria. We performed a literature search and surveyed our SSC membership to better define the term when applied to medical and intensive care unit patients. The most common heparin dosing strategy reported in the literature (5...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of thrombosis and haemostasis 2023-12, Vol.21 (12), p.3649-3657
Hauptverfasser: Levy, Jerrold H., Sniecinski, Roman M., Rocca, Bianca, Ghadimi, Kamrouz, Douketis, James, Frere, Corinne, Helms, Julie, Iba, Toshiaki, Koster, Andreas, Lech, Tara K., Maier, Cheryl L., Neal, Mathew D., Scarlestscu, Ecatarina, Spyropoulos, Alex, Steiner, Marie E., Tafur, Alfonso J., Tanaka, Kenichi A., Connors, Jean M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3657
container_issue 12
container_start_page 3649
container_title Journal of thrombosis and haemostasis
container_volume 21
creator Levy, Jerrold H.
Sniecinski, Roman M.
Rocca, Bianca
Ghadimi, Kamrouz
Douketis, James
Frere, Corinne
Helms, Julie
Iba, Toshiaki
Koster, Andreas
Lech, Tara K.
Maier, Cheryl L.
Neal, Mathew D.
Scarlestscu, Ecatarina
Spyropoulos, Alex
Steiner, Marie E.
Tafur, Alfonso J.
Tanaka, Kenichi A.
Connors, Jean M.
description The term heparin resistance (HR) is used by clinicians without specific criteria. We performed a literature search and surveyed our SSC membership to better define the term when applied to medical and intensive care unit patients. The most common heparin dosing strategy reported in the literature (53%) and by survey respondents (80.4%) was the use of weight-based dosing. Heparin monitoring results were similar based on the proportion of publications and respondents that reported the use of anti-Xa and activated partial thromboplastin time. The most common literature definition of HR was >35 000 U/d, but no consensus was reported among survey respondents regarding weight-based and the total dose of heparin when determining resistance. Respondent consensus on treating HR included antithrombin supplementation, direct thrombin inhibitors, or administering more heparin as the strategies available for treating HR. A range of definitions for HR exist. Given the common use of heparin weight-based dosing, future publications employing the term HR should include weight-based definitions, monitoring assay, and target level used. Further work is needed to develop a consensus for defining HR. •The term heparin resistance is commonly used without a specific definition or clarity.•We performed a literature search and Scientific and Standardization Committee survey to identify published definitions and current clinical practice definitions of heparin resistance.•Definitions varied widely, with heterogeneity in total threshold heparin doses, weight-based dosing, and management.•Further work is needed to develop a consensus for the definition of heparin resistance.
doi_str_mv 10.1016/j.jtha.2023.08.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2857840373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1538783623006414</els_id><sourcerecordid>2857840373</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-7c01b81ca6fc6c6a701799ec930fc7c4a753fb7f1e6701ab1f1c58127898e5d73</originalsourceid><addsrcrecordid>eNp9kMtOxCAUhonReH8BF4alm6lQpoUaN6ZexsREkxnXhNKDw2RaRqAmvoDPLeOoceUKyPn-_4QPoRNKMkpoeb7IFnGuspzkLCMiI5RtoX1aMDHigpXbf-576CCEBSG0KnKyi_YYL2lVVuN99HENxva2f8FzWClve-wh2BBVr-ECa9d1Q2-1itb12HjX4TgHfD-dTfB0WuPp0KwRGyMAdgY_gbduBT7xb4BV3-La25jyS1wrD3g2TxWNSwu-hhPoXFqVnkdox6hlgOPv8xA9397M6sno4fHuvr56GOkxIXHENaGNoFqVRpe6VJxQXlWgK0aM5nqseMFMww2FMo1UQw3VhaA5F5WAouXsEJ1telfevQ4Qouxs0LBcqh7cEGQuCi7GhHGW0HyDau9C8GDkyttO-XdJiVz7lwu59i_X_iURMvlPodPv_qHpoP2N_AhPwOUGgPTLNwteBm0hyW6tBx1l6-x__Z8XQZiM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2857840373</pqid></control><display><type>article</type><title>Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Levy, Jerrold H. ; Sniecinski, Roman M. ; Rocca, Bianca ; Ghadimi, Kamrouz ; Douketis, James ; Frere, Corinne ; Helms, Julie ; Iba, Toshiaki ; Koster, Andreas ; Lech, Tara K. ; Maier, Cheryl L. ; Neal, Mathew D. ; Scarlestscu, Ecatarina ; Spyropoulos, Alex ; Steiner, Marie E. ; Tafur, Alfonso J. ; Tanaka, Kenichi A. ; Connors, Jean M.</creator><creatorcontrib>Levy, Jerrold H. ; Sniecinski, Roman M. ; Rocca, Bianca ; Ghadimi, Kamrouz ; Douketis, James ; Frere, Corinne ; Helms, Julie ; Iba, Toshiaki ; Koster, Andreas ; Lech, Tara K. ; Maier, Cheryl L. ; Neal, Mathew D. ; Scarlestscu, Ecatarina ; Spyropoulos, Alex ; Steiner, Marie E. ; Tafur, Alfonso J. ; Tanaka, Kenichi A. ; Connors, Jean M.</creatorcontrib><description>The term heparin resistance (HR) is used by clinicians without specific criteria. We performed a literature search and surveyed our SSC membership to better define the term when applied to medical and intensive care unit patients. The most common heparin dosing strategy reported in the literature (53%) and by survey respondents (80.4%) was the use of weight-based dosing. Heparin monitoring results were similar based on the proportion of publications and respondents that reported the use of anti-Xa and activated partial thromboplastin time. The most common literature definition of HR was &gt;35 000 U/d, but no consensus was reported among survey respondents regarding weight-based and the total dose of heparin when determining resistance. Respondent consensus on treating HR included antithrombin supplementation, direct thrombin inhibitors, or administering more heparin as the strategies available for treating HR. A range of definitions for HR exist. Given the common use of heparin weight-based dosing, future publications employing the term HR should include weight-based definitions, monitoring assay, and target level used. Further work is needed to develop a consensus for defining HR. •The term heparin resistance is commonly used without a specific definition or clarity.•We performed a literature search and Scientific and Standardization Committee survey to identify published definitions and current clinical practice definitions of heparin resistance.•Definitions varied widely, with heterogeneity in total threshold heparin doses, weight-based dosing, and management.•Further work is needed to develop a consensus for the definition of heparin resistance.</description><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1016/j.jtha.2023.08.013</identifier><identifier>PMID: 37619694</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Anticoagulants - adverse effects ; anticoagulation ; Antithrombins - therapeutic use ; Communication ; COVID-19 ; Critical Care ; ECMO ; Hemostasis ; heparin ; Heparin - adverse effects ; Humans ; Partial Thromboplastin Time ; resistance ; sensitivity ; Thrombosis - drug therapy</subject><ispartof>Journal of thrombosis and haemostasis, 2023-12, Vol.21 (12), p.3649-3657</ispartof><rights>2023 International Society on Thrombosis and Haemostasis</rights><rights>Copyright © 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-7c01b81ca6fc6c6a701799ec930fc7c4a753fb7f1e6701ab1f1c58127898e5d73</citedby><cites>FETCH-LOGICAL-c400t-7c01b81ca6fc6c6a701799ec930fc7c4a753fb7f1e6701ab1f1c58127898e5d73</cites><orcidid>0000-0001-6025-1379 ; 0000-0002-3175-461X ; 0000-0001-8304-6423 ; 0000-0002-9287-7541 ; 0000-0002-0255-4088 ; 0000-0002-5051-1365 ; 0000-0002-5556-3623 ; 0000-0001-9713-6403 ; 0000-0003-3766-4962 ; 0009-0006-1186-7808 ; 0000-0002-0179-1903 ; 0000-0001-6445-582X ; 0000-0003-4044-2674 ; 0000-0001-6303-4732 ; 0000-0003-4766-3314 ; 0000-0003-4169-1920 ; 0000-0001-5288-0394 ; 0000-0003-0895-6800</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37619694$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Levy, Jerrold H.</creatorcontrib><creatorcontrib>Sniecinski, Roman M.</creatorcontrib><creatorcontrib>Rocca, Bianca</creatorcontrib><creatorcontrib>Ghadimi, Kamrouz</creatorcontrib><creatorcontrib>Douketis, James</creatorcontrib><creatorcontrib>Frere, Corinne</creatorcontrib><creatorcontrib>Helms, Julie</creatorcontrib><creatorcontrib>Iba, Toshiaki</creatorcontrib><creatorcontrib>Koster, Andreas</creatorcontrib><creatorcontrib>Lech, Tara K.</creatorcontrib><creatorcontrib>Maier, Cheryl L.</creatorcontrib><creatorcontrib>Neal, Mathew D.</creatorcontrib><creatorcontrib>Scarlestscu, Ecatarina</creatorcontrib><creatorcontrib>Spyropoulos, Alex</creatorcontrib><creatorcontrib>Steiner, Marie E.</creatorcontrib><creatorcontrib>Tafur, Alfonso J.</creatorcontrib><creatorcontrib>Tanaka, Kenichi A.</creatorcontrib><creatorcontrib>Connors, Jean M.</creatorcontrib><title>Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>The term heparin resistance (HR) is used by clinicians without specific criteria. We performed a literature search and surveyed our SSC membership to better define the term when applied to medical and intensive care unit patients. The most common heparin dosing strategy reported in the literature (53%) and by survey respondents (80.4%) was the use of weight-based dosing. Heparin monitoring results were similar based on the proportion of publications and respondents that reported the use of anti-Xa and activated partial thromboplastin time. The most common literature definition of HR was &gt;35 000 U/d, but no consensus was reported among survey respondents regarding weight-based and the total dose of heparin when determining resistance. Respondent consensus on treating HR included antithrombin supplementation, direct thrombin inhibitors, or administering more heparin as the strategies available for treating HR. A range of definitions for HR exist. Given the common use of heparin weight-based dosing, future publications employing the term HR should include weight-based definitions, monitoring assay, and target level used. Further work is needed to develop a consensus for defining HR. •The term heparin resistance is commonly used without a specific definition or clarity.•We performed a literature search and Scientific and Standardization Committee survey to identify published definitions and current clinical practice definitions of heparin resistance.•Definitions varied widely, with heterogeneity in total threshold heparin doses, weight-based dosing, and management.•Further work is needed to develop a consensus for the definition of heparin resistance.</description><subject>Anticoagulants - adverse effects</subject><subject>anticoagulation</subject><subject>Antithrombins - therapeutic use</subject><subject>Communication</subject><subject>COVID-19</subject><subject>Critical Care</subject><subject>ECMO</subject><subject>Hemostasis</subject><subject>heparin</subject><subject>Heparin - adverse effects</subject><subject>Humans</subject><subject>Partial Thromboplastin Time</subject><subject>resistance</subject><subject>sensitivity</subject><subject>Thrombosis - drug therapy</subject><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOxCAUhonReH8BF4alm6lQpoUaN6ZexsREkxnXhNKDw2RaRqAmvoDPLeOoceUKyPn-_4QPoRNKMkpoeb7IFnGuspzkLCMiI5RtoX1aMDHigpXbf-576CCEBSG0KnKyi_YYL2lVVuN99HENxva2f8FzWClve-wh2BBVr-ECa9d1Q2-1itb12HjX4TgHfD-dTfB0WuPp0KwRGyMAdgY_gbduBT7xb4BV3-La25jyS1wrD3g2TxWNSwu-hhPoXFqVnkdox6hlgOPv8xA9397M6sno4fHuvr56GOkxIXHENaGNoFqVRpe6VJxQXlWgK0aM5nqseMFMww2FMo1UQw3VhaA5F5WAouXsEJ1telfevQ4Qouxs0LBcqh7cEGQuCi7GhHGW0HyDau9C8GDkyttO-XdJiVz7lwu59i_X_iURMvlPodPv_qHpoP2N_AhPwOUGgPTLNwteBm0hyW6tBx1l6-x__Z8XQZiM</recordid><startdate>202312</startdate><enddate>202312</enddate><creator>Levy, Jerrold H.</creator><creator>Sniecinski, Roman M.</creator><creator>Rocca, Bianca</creator><creator>Ghadimi, Kamrouz</creator><creator>Douketis, James</creator><creator>Frere, Corinne</creator><creator>Helms, Julie</creator><creator>Iba, Toshiaki</creator><creator>Koster, Andreas</creator><creator>Lech, Tara K.</creator><creator>Maier, Cheryl L.</creator><creator>Neal, Mathew D.</creator><creator>Scarlestscu, Ecatarina</creator><creator>Spyropoulos, Alex</creator><creator>Steiner, Marie E.</creator><creator>Tafur, Alfonso J.</creator><creator>Tanaka, Kenichi A.</creator><creator>Connors, Jean M.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6025-1379</orcidid><orcidid>https://orcid.org/0000-0002-3175-461X</orcidid><orcidid>https://orcid.org/0000-0001-8304-6423</orcidid><orcidid>https://orcid.org/0000-0002-9287-7541</orcidid><orcidid>https://orcid.org/0000-0002-0255-4088</orcidid><orcidid>https://orcid.org/0000-0002-5051-1365</orcidid><orcidid>https://orcid.org/0000-0002-5556-3623</orcidid><orcidid>https://orcid.org/0000-0001-9713-6403</orcidid><orcidid>https://orcid.org/0000-0003-3766-4962</orcidid><orcidid>https://orcid.org/0009-0006-1186-7808</orcidid><orcidid>https://orcid.org/0000-0002-0179-1903</orcidid><orcidid>https://orcid.org/0000-0001-6445-582X</orcidid><orcidid>https://orcid.org/0000-0003-4044-2674</orcidid><orcidid>https://orcid.org/0000-0001-6303-4732</orcidid><orcidid>https://orcid.org/0000-0003-4766-3314</orcidid><orcidid>https://orcid.org/0000-0003-4169-1920</orcidid><orcidid>https://orcid.org/0000-0001-5288-0394</orcidid><orcidid>https://orcid.org/0000-0003-0895-6800</orcidid></search><sort><creationdate>202312</creationdate><title>Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis</title><author>Levy, Jerrold H. ; Sniecinski, Roman M. ; Rocca, Bianca ; Ghadimi, Kamrouz ; Douketis, James ; Frere, Corinne ; Helms, Julie ; Iba, Toshiaki ; Koster, Andreas ; Lech, Tara K. ; Maier, Cheryl L. ; Neal, Mathew D. ; Scarlestscu, Ecatarina ; Spyropoulos, Alex ; Steiner, Marie E. ; Tafur, Alfonso J. ; Tanaka, Kenichi A. ; Connors, Jean M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-7c01b81ca6fc6c6a701799ec930fc7c4a753fb7f1e6701ab1f1c58127898e5d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anticoagulants - adverse effects</topic><topic>anticoagulation</topic><topic>Antithrombins - therapeutic use</topic><topic>Communication</topic><topic>COVID-19</topic><topic>Critical Care</topic><topic>ECMO</topic><topic>Hemostasis</topic><topic>heparin</topic><topic>Heparin - adverse effects</topic><topic>Humans</topic><topic>Partial Thromboplastin Time</topic><topic>resistance</topic><topic>sensitivity</topic><topic>Thrombosis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Levy, Jerrold H.</creatorcontrib><creatorcontrib>Sniecinski, Roman M.</creatorcontrib><creatorcontrib>Rocca, Bianca</creatorcontrib><creatorcontrib>Ghadimi, Kamrouz</creatorcontrib><creatorcontrib>Douketis, James</creatorcontrib><creatorcontrib>Frere, Corinne</creatorcontrib><creatorcontrib>Helms, Julie</creatorcontrib><creatorcontrib>Iba, Toshiaki</creatorcontrib><creatorcontrib>Koster, Andreas</creatorcontrib><creatorcontrib>Lech, Tara K.</creatorcontrib><creatorcontrib>Maier, Cheryl L.</creatorcontrib><creatorcontrib>Neal, Mathew D.</creatorcontrib><creatorcontrib>Scarlestscu, Ecatarina</creatorcontrib><creatorcontrib>Spyropoulos, Alex</creatorcontrib><creatorcontrib>Steiner, Marie E.</creatorcontrib><creatorcontrib>Tafur, Alfonso J.</creatorcontrib><creatorcontrib>Tanaka, Kenichi A.</creatorcontrib><creatorcontrib>Connors, Jean M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Levy, Jerrold H.</au><au>Sniecinski, Roman M.</au><au>Rocca, Bianca</au><au>Ghadimi, Kamrouz</au><au>Douketis, James</au><au>Frere, Corinne</au><au>Helms, Julie</au><au>Iba, Toshiaki</au><au>Koster, Andreas</au><au>Lech, Tara K.</au><au>Maier, Cheryl L.</au><au>Neal, Mathew D.</au><au>Scarlestscu, Ecatarina</au><au>Spyropoulos, Alex</au><au>Steiner, Marie E.</au><au>Tafur, Alfonso J.</au><au>Tanaka, Kenichi A.</au><au>Connors, Jean M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2023-12</date><risdate>2023</risdate><volume>21</volume><issue>12</issue><spage>3649</spage><epage>3657</epage><pages>3649-3657</pages><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>The term heparin resistance (HR) is used by clinicians without specific criteria. We performed a literature search and surveyed our SSC membership to better define the term when applied to medical and intensive care unit patients. The most common heparin dosing strategy reported in the literature (53%) and by survey respondents (80.4%) was the use of weight-based dosing. Heparin monitoring results were similar based on the proportion of publications and respondents that reported the use of anti-Xa and activated partial thromboplastin time. The most common literature definition of HR was &gt;35 000 U/d, but no consensus was reported among survey respondents regarding weight-based and the total dose of heparin when determining resistance. Respondent consensus on treating HR included antithrombin supplementation, direct thrombin inhibitors, or administering more heparin as the strategies available for treating HR. A range of definitions for HR exist. Given the common use of heparin weight-based dosing, future publications employing the term HR should include weight-based definitions, monitoring assay, and target level used. Further work is needed to develop a consensus for defining HR. •The term heparin resistance is commonly used without a specific definition or clarity.•We performed a literature search and Scientific and Standardization Committee survey to identify published definitions and current clinical practice definitions of heparin resistance.•Definitions varied widely, with heterogeneity in total threshold heparin doses, weight-based dosing, and management.•Further work is needed to develop a consensus for the definition of heparin resistance.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>37619694</pmid><doi>10.1016/j.jtha.2023.08.013</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6025-1379</orcidid><orcidid>https://orcid.org/0000-0002-3175-461X</orcidid><orcidid>https://orcid.org/0000-0001-8304-6423</orcidid><orcidid>https://orcid.org/0000-0002-9287-7541</orcidid><orcidid>https://orcid.org/0000-0002-0255-4088</orcidid><orcidid>https://orcid.org/0000-0002-5051-1365</orcidid><orcidid>https://orcid.org/0000-0002-5556-3623</orcidid><orcidid>https://orcid.org/0000-0001-9713-6403</orcidid><orcidid>https://orcid.org/0000-0003-3766-4962</orcidid><orcidid>https://orcid.org/0009-0006-1186-7808</orcidid><orcidid>https://orcid.org/0000-0002-0179-1903</orcidid><orcidid>https://orcid.org/0000-0001-6445-582X</orcidid><orcidid>https://orcid.org/0000-0003-4044-2674</orcidid><orcidid>https://orcid.org/0000-0001-6303-4732</orcidid><orcidid>https://orcid.org/0000-0003-4766-3314</orcidid><orcidid>https://orcid.org/0000-0003-4169-1920</orcidid><orcidid>https://orcid.org/0000-0001-5288-0394</orcidid><orcidid>https://orcid.org/0000-0003-0895-6800</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1538-7836
ispartof Journal of thrombosis and haemostasis, 2023-12, Vol.21 (12), p.3649-3657
issn 1538-7836
1538-7836
language eng
recordid cdi_proquest_miscellaneous_2857840373
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Anticoagulants - adverse effects
anticoagulation
Antithrombins - therapeutic use
Communication
COVID-19
Critical Care
ECMO
Hemostasis
heparin
Heparin - adverse effects
Humans
Partial Thromboplastin Time
resistance
sensitivity
Thrombosis - drug therapy
title Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T01%3A58%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Defining%20heparin%20resistance:%20communication%20from%20the%20ISTH%20SSC%20Subcommittee%20of%20Perioperative%20and%20Critical%20Care%20Thrombosis%20and%20Hemostasis&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=Levy,%20Jerrold%20H.&rft.date=2023-12&rft.volume=21&rft.issue=12&rft.spage=3649&rft.epage=3657&rft.pages=3649-3657&rft.issn=1538-7836&rft.eissn=1538-7836&rft_id=info:doi/10.1016/j.jtha.2023.08.013&rft_dat=%3Cproquest_cross%3E2857840373%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2857840373&rft_id=info:pmid/37619694&rft_els_id=S1538783623006414&rfr_iscdi=true